KR20120125230A - 급성 홍반 치료 또는 예방 방법 - Google Patents

급성 홍반 치료 또는 예방 방법 Download PDF

Info

Publication number
KR20120125230A
KR20120125230A KR1020127013737A KR20127013737A KR20120125230A KR 20120125230 A KR20120125230 A KR 20120125230A KR 1020127013737 A KR1020127013737 A KR 1020127013737A KR 20127013737 A KR20127013737 A KR 20127013737A KR 20120125230 A KR20120125230 A KR 20120125230A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
adrenergic receptor
receptor agonist
acute erythema
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127013737A
Other languages
English (en)
Korean (ko)
Inventor
필립 안드레스
크리스티안 로쉬
마이클 그레이버
Original Assignee
갈더마파마 에스.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈더마파마 에스.아. filed Critical 갈더마파마 에스.아.
Publication of KR20120125230A publication Critical patent/KR20120125230A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127013737A 2009-10-26 2010-10-19 급성 홍반 치료 또는 예방 방법 Ceased KR20120125230A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25480509P 2009-10-26 2009-10-26
US61/254,805 2009-10-26
PCT/US2010/053198 WO2011053487A1 (en) 2009-10-26 2010-10-19 Methods of treating or preventing acute erythema

Publications (1)

Publication Number Publication Date
KR20120125230A true KR20120125230A (ko) 2012-11-14

Family

ID=43922456

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013737A Ceased KR20120125230A (ko) 2009-10-26 2010-10-19 급성 홍반 치료 또는 예방 방법

Country Status (12)

Country Link
US (1) US20110224216A1 (cg-RX-API-DMAC7.html)
EP (1) EP2493309A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013508454A (cg-RX-API-DMAC7.html)
KR (1) KR20120125230A (cg-RX-API-DMAC7.html)
CN (1) CN102711471A (cg-RX-API-DMAC7.html)
AU (1) AU2010313643B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012009891A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779063A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012004890A (cg-RX-API-DMAC7.html)
NZ (1) NZ600125A (cg-RX-API-DMAC7.html)
RU (1) RU2012122983A (cg-RX-API-DMAC7.html)
WO (1) WO2011053487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
WO2011117378A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
RU2587041C2 (ru) * 2010-06-30 2016-06-10 Галдерма Ресерч Энд Девелопмент Способ предотвращения или лечения опухоли кожи
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EP2994120B1 (en) * 2013-05-06 2019-10-09 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
EP2962689B1 (en) * 2014-06-30 2018-04-11 Galderma S.A. Method of treating flushing associated with carcinoid tumors and carcinoid syndrome
CN106361733A (zh) * 2015-07-22 2017-02-01 刘里远 外用经穴激动剂
US10617688B2 (en) 2016-03-22 2020-04-14 Doris Maria HEXSEL Use of pharmaceutical composition for the treatment of skin erythema in poikilodermas
FR3119986B1 (fr) * 2021-02-19 2024-02-16 Tarian Pharma Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911196B2 (en) * 2002-07-31 2005-06-28 Samir I. Hamtini Topical medicament for treating nappy rash
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050226899A1 (en) * 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
ES2424644T3 (es) * 2004-05-25 2013-10-07 Galderma Pharma S.A. Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US7709014B2 (en) * 2005-10-17 2010-05-04 Yu Ruey J Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
CN103298472A (zh) * 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US20120101104A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel compositions and methods of use
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Also Published As

Publication number Publication date
BR112012009891A2 (pt) 2015-09-29
WO2011053487A1 (en) 2011-05-05
NZ600125A (en) 2014-05-30
CN102711471A (zh) 2012-10-03
AU2010313643B2 (en) 2015-11-12
EP2493309A1 (en) 2012-09-05
AU2010313643A1 (en) 2012-06-07
JP2013508454A (ja) 2013-03-07
EP2493309A4 (en) 2013-05-01
RU2012122983A (ru) 2014-01-27
US20110224216A1 (en) 2011-09-15
CA2779063A1 (en) 2011-05-05
MX2012004890A (es) 2012-09-28

Similar Documents

Publication Publication Date Title
AU2010313643B2 (en) Methods of treating or preventing acute erythema
KR101257046B1 (ko) 염증성 피부 질환을 치료하거나 예방하기 위한 화합물,제형 및 방법
CN102743380B (zh) 用于治疗或预防酒渣鼻的化合物、制剂和方法
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20180360827A1 (en) Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
CN105579042A (zh) 治疗皮肤增厚的方法
AU2016216627B2 (en) Pharmaceutical compositions comprising 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US10201535B2 (en) Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
KR20140068029A (ko) 4-브로모-n-(이미다졸리딘-2-일리덴)-1h-벤즈이미다졸-5-아민을 포함하는 피부병 치료용 약제학적 조성물들
HK1177102A (en) Methods of treating or preventing acute erythema
KR20190017801A (ko) 티몰롤을 포함하는 조성물 및 국소 투여에 의한 주사의 치료에 있어서의 이들의 용도
HK1174049A (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161109

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20170817

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171116

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170817

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20161109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I